Prix Galien

Referenties Luxturna ® 1. SmPC Voretigene Neparvovec (Luxturna) 2020. Beschikbaar op https://www.novartis.nl/medicijnen/luxturna 2. Chung DC, BertelsenM, Lorenz B, et al. The Natural History of Inherited Retinal Dystrophy Due to Biallelic Mutations in the RPE65 Gene. Am J Ophthalmol. 2019;199:58-70. doi:10.1016/j. ajo.2018.09.024 3. Lloyd A, Piglowska N, Ciulla T, et al. Estimation of impact of RPE65- mediated inherited retinal disease on quality of life and the potential benefits of gene therapy. Br J Ophthalmol. Published online January 18, 2019:bjophthalmol-2018-313089. doi:10.1136/ bjophthalmol-2018-313089 4. www.horizonscangeneesmiddelen.nl/geneesmiddelen/voretigene- neparvovec-neurologische-aandoeningen-oogaandoeningen/versie7 (8 december 2020). 5. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet (London, England). 2017;390(10097):849-860. doi:10.1016/S0140-6736(17)31868-8 6. EuropeanMedicines Agency (EMA). EPAR Voretigene Neparvovec (Luxturna). 2018 7. Maguire AM, Russell S, Wellman JA, et al. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65Mutation– Associated Inherited Retinal Dystrophy. Ophthalmology. 2019;126(9):1273-1285. doi:10.1016/j.ophtha.2019.06.017 8. Leroy BP. Webcast: Retinal Gene Therapy and the Patient Experience. EURETINA 2019. https://eyetube.net/collections/retinal-gene- therapy/retinal-gene-therapy-and-the-patient-experience/ (password: novartis2019) Referenties Ondexxya ® 1. SmPCOndexxya ® , vanaf juni 2019 2. https://www.ema.europa.eu/en/medicines/human/EPAR/ ondexxya#authorisation-details-section 3. Kuramatsu JB, Sembill JA, Huttner HB. Critical Care. 2019 Jun 6;23:206 4. CammAJ et al. Europace. 2010 Oct;12(10):1360–1420 5. Piccini JP et al .; Eur Heart J. 2014; 35 (28): 1873-1880 6. Hero C et al. Eur Heart J. 2015; 36: 1264-1272 7. Hankey GJ et al. Stroke. 2014;45:1304–1312 8. Lu G et al. NatureMed. 2013;19(4):446–451 9. Siegal DMet al. N Engl J Med. 2015;373:2413–2424. 7 10. Connolly S et al. N Engl J Med. 2019 Apr 4;380(14):1326–1335 Referenties Rybelsus ® 1. NHG-standaard Diabetes mellitus type 2, www.nhg.org 2. Diabetes mellitus type 2 in de tweede lijn, Nederlandse Internisten Vereniging; 2018, https://richtlijnendatabase.nl 3. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046-55 4. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of Once-Weekly Dulaglutide Versus Insulin Glargine in PatientsWith Type 2 Diabetes onMetformin and Glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241-9 5. Aroda VR, Bain SC, Cariou B, Piletic M, Rose L, AxelsenM, et al. Efficacy and safety of once-weekly semaglutide versus once- daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology. 2017;5(5):355-66 6. Zorginstituut Nederland. Bijlage 2 voorwaarden GLP-1 receptoragonisten toegevoegd aan orale medicatie, https:// www.farmacotherapeutischkompas.nl/algemeen/regeling- zorgverzekering#bijlage-2-bij-de-regeling-zorgverzekering 7. Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Therapeutic Advances in Endocrinology andMetabolism. 2019;10:2042018819844694 8. Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt- Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 repeptor agonist. Science Translational Medicine. 2018;10(467) 9. Pratley R, Amod A, Hoff ST, Kadowki T, Lingvay I, NauckM, et al. Oral semaglutide versus subcutaneous liraglutide ad placebo in type 2 diabetes (PIONEER $): a randomsied, double-blind, phase 3a trial. Lancet (London, England). 2019;394(10192):39-50 10. Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes, Obesity & Metabolism. 2020;22(8):1263-77 NL21RYB00016 Referenties Veklury ® 1. Novel Coronavirus (2019-nCoV) SITUATION REPORT – 1 21 JANUARY 2020. Available from: https://www.who.int/docs/default- source/coronaviruse/situation-reports/20200121-sitrep-1-2019- ncov.pdf. Accessed: February 2021 2. Sheahan TP et al. Sci Trans Med. 2017 3. Williamson B, et al. Nature. 2020;585:273-276. https://doi. org/10.1038/s41586-020-2423-5 4. Grein et al. NEJM June 2020 5. EPAR Veklury. Available from: https://www.ema.europa.eu/en/ medicines/human/EPAR/veklury. Accessed: February 2021 6. Summary of product characteristics Veklury, latest version. Available from: https://www.geneesmiddeleninformatiebank. nl/ords/f?p=111:3::SEARCH:NO::P0_DOMAIN,P0_LANG,P3_ RVG1:H,NL,126777. Accessed: February 2021 7. Tchesnokov EP, et al. J Biol Chem. 2020. https://dx.doi.org/10.1074/ jbc.AC120.015720 8. Beigel JH et al. NEJMOctober 2020 9. About Veklury. Available from: https://www.gilead.com/purpose/ advancing-global-health/covid-19/about-veklury. Accessed February 2021 10. Gilead. Development of remdesivir. Available from: https:// www.gilead.com/-/media/files/pdfs/medicines/covid-19/ veklury/veklury-remdesivir-development-backgrounder. pdf?la=en&hash=3B814B9901483A3941ACF9D066056366. Accessed February 2021 11. World Health Organisation. WHO Timeline – COVID-19. Available from: https://www.who.int/news-room/detail/27-04-2020-who- timeline---covid-19. Accessed November 2020. 12. Working to supply Veklury for COVID-19. Available from: https:// www.gilead.com/purpose/advancing-global-health/covid-19/working- to-supply-veklury-for-covid-19. Accessed February 2021 13. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. doi: 10.1056/NEJMoa2015301. pmid:32459919 14. Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A et al. Effects of Remdesivir vs. Standard Care on Clinical Status at 11-Day in patients withModerate COVID-19: A Randomized Clinical Trial. JAMA. Published online August 21, 2020. doi: 10.1001/jama.2020.16349. pmid:32821939 15. Gordon CJ, et al. J Biol Chem. 2020; 295: 6785–6797 16. An update on COVID-19 fromGilead’s chairman &CEO. Available from: https://stories.gilead.com/articles/an-update-on-covid-19- from-our-chairman-and-ceo. Accessed February 2021 Referenties Vitrakvi ® 1. EMA approval VITRAKVI (larotrectinib). 2019. https://www.ema. europa.eu/en/medicines/human/EPAR/vitrakvi 2. SmPC VITRAKVI® (larotrectinib), 08/2020. 3. Hong DS, et al. Lancet Oncol 2020;21(4):531-540 4. Drilon A, et al. J Clin Oncol 2019;37(suppl): Abstract 2006. Oral presentation at ASCO 2019 5. Italiano A, et al. Cancers 2020, 12, 3246 6. Kummar S, et al. J Clin Oncol 2020; 38(suppl): Abstract 3614. Poster presentation at ASCO 2020 7. Marieke ten Katen en Rob Ramaker, Elsevier weekblad, 2 november 2019: 68-71 8. Laetsch TW, et al. J Clin Oncol 2017; 35: 10510 Referenties Yescarta ® 1. Concept Richtlijn Diffuus grootcellig B-cel non-Hodgkin lymfoom (DLBCL), 2019 2. CrumpM, Neelapu SS, et al. Blood. 2017 Oct 19;130(16):1800- 1808 3. SmPC Yescarta 4. Locke et al. Lancet Oncol. 2019;20(1):31-42 5. I. Hegger, R.A.A. Vonk, M.Weda, Toekomstverwachtingen over ATMPs, RIVMBriefrapport 2017-0168 6. EMA. Yescarta EPAR Annex Summary of Product Characteristics SmPC (2018) 43